Key Points {#FPar1}
==========

This systematic review adds to previous reviews of the assessment and treatment of pain in people with dementia, with a particular focus on studies investigating the direct efficacy of analgesics on pain intensity.The review underlines current challenges: thorough pain assessment is poorly implemented, observational pain instruments are rarely tested for responsiveness; therefore, sound evaluation of pain management strategies is lacking and evidence for efficacy and safety of analgesics is largely missing.

Introduction {#Sec1}
============

It is widely acknowledged that the assessment and treatment of acute and persistent pain is a complex entity in nursing home patients with Alzheimer's disease \[[@CR1]\]. There are two extreme endpoints related to these challenges. On one side, the prevalence of undiagnosed and untreated pain is described as unacceptably high in the primary health care system, with reported prevalence up to 32 % in home-dwelling people with dementia \[[@CR2]\] and about 60 % in nursing home patients with and without dementia \[[@CR3], [@CR4]\]. On the other hand, recent reports document increasing analgesic drug prescription trends, especially in Scandinavia \[[@CR5]--[@CR7]\], regardless of the potential side effects \[[@CR8]\] and the prevalent polypharmacy in these patients. This picture is getting even more complex in light of the individual persons who experience the pain. Most of these people develop changes in their physical function caused by multimorbidity and increased vulnerability \[[@CR9]\]. They have high needs for motivated and competent nursing home staff \[[@CR10]\], implementation of research-based knowledge \[[@CR11]\], routine use of validated pain assessment tools \[[@CR12], [@CR13]\], and guidelines for appropriate analgesic treatment \[[@CR14]\]. This complex clinical situation is illustrated in the case of Mr. K (Fig. [1](#Fig1){ref-type="fig"}a, b).Fig. 1**a** The case of Mr. K. **b** Conclusion of the case of Mr. K. *MOBID-2* Mobilization-Observation-Behavior-Intensity-Dementia-2 Pain Scale

Alzheimer's dementia (AD) and vascular dementia (VaD) are age-related diseases that have a major impact on health care resources. At present, 35 million people worldwide have dementia, with an expected increase to 115 million by 2050 \[[@CR15]\]. In advanced stages of dementia, AD is often combined with VaD to mixed dementia (AD-VaD), suggested to be the most prevalent in nursing home patients \[[@CR4], [@CR16]\]. These people are more prone to central, neuropathic pain, because lesions in the white matter substance disturb the connections in the pain system \[[@CR17]\].

Despite over a century of scientific endeavor, effective curative treatment options for these diseases are still lacking, and increasing frailty and disabilities require institutional care for more and more individuals. During the course of the disease, the slight progress of AD substantially affects the motivational and cognitive structures of the pain network, usually responsible for properly assigning the meaning to pain \[[@CR1], [@CR12], [@CR13]\].

In addition to memory disturbances, dementia is commonly accompanied by neuropsychiatric symptoms \[[@CR18]\] such as agitation and aggression, depression and apathy, eating and appetite disturbances, and sleeping disorders \[[@CR19]\]. It is suggested that the causes of these symptoms are multifactorial, based on chemical, anatomical, and transmitter changes in the brain and/or related to unmet needs. One important trigger for neuropsychiatric symptoms may be undiagnosed and untreated pain \[[@CR20]\]. However, proper assessment and treatment of pain in people with dementia is hampered by the challenge that those in advanced stages of the disease are no longer able to describe their suffering and to give precise self-reports regarding the intensity, location, and duration of the pain \[[@CR1]\]. In addition, they are not able to report appropriate pain relieving effects or side effects in connection with the pain treatment \[[@CR13]\].

General agreement exists that proper assessment of pain is a prerequisite for proper treatment. During this process, if self-report is no longer possible, a validated, reliable, and responsive observational, behavioral pain assessment tool is required. This means that a proxy rater, usually a nurse who knows the patient over time, should be able to interpret the patient's behavior and transfer it into a measure of pain presence and preferably also into pain intensity \[[@CR16], [@CR21]\]. During the last 25 years, about 30 tools have been developed and tested to assess pain in people with dementia. Although several review articles present overviews over such tools \[[@CR22]--[@CR29]\], there is no general agreement on which instrument should be recommended. We suggest, however, that clinicians and researchers worldwide appreciate different tools, possibly in relation to the country in which the respective instrument has been developed, the availability in that specific country and language, and the recommendations by national and regional procedures and guidelines.

Dementia is a life-limiting disease that requires treatment and care in nursing homes or hospitals for almost all patients at the end of life \[[@CR30]\]. This means that the identification and management of pain in the final weeks and hours should also be addressed as a key topic \[[@CR31]\].

Nonetheless, the effectiveness of a pain treatment strategy during nursing home stay and at the end of life cannot be guaranteed by the amount of analgesic drug prescriptions alone. The way to succeed includes proper assessment, treatment, and evaluation of the treatment effect by re-assessment, again using a validated pain tool. Clearly, this requires nursing home staff who are skilled in conducting these procedures and a physician who is a specialist on dementia assessment and communicates well with the multidisciplinary team.

Although there have been other systematic reviews on pain in dementia, for instance, on the reliability and validity of pain scales, this one is the first to look at important pain management features, such as outcome measures for pain treatment, responsiveness of pain observation scales, and efficacy of pain medication. The main goal of this systematic review is the identification of studies that directly investigate the efficacy of different analgesics on pain intensity or typical behavior that might be related to pain in people with dementia, during nursing home stay and at the end of life. In order to evaluate the quality of the included studies, we additionally did an updated search based on recent systematic reviews of behavioral pain assessment tools in people with dementia published by the authors \[[@CR1], [@CR13], [@CR21], [@CR32]\]. The purpose of this was to be able to ascertain whether the observational pain tools used in the included efficacy trials were tested for responsiveness. Thus, we will explore the following questions:Which analgesics are efficacy-tested by clinical or randomized controlled trials in people with dementia?Which outcome measures have been used to identify pain, pain behavior, and/or pain treatment efficacy?Which of the pain assessment tools used for people with dementia are responsive to change in pain intensity scores, and thus, adequate to use in a pain treatment efficacy trial?

Method {#Sec2}
======

This systematic review of the literature aims to gather fully randomized controlled studies with comparator groups or open studies with more than ten participants that investigate the efficacy of treating pain on pain intensity scores and/or behavioral disturbances and neuropsychiatric symptoms in people with dementia. By this, we will describe analgesic interventions and assessment procedures related to the intervention. We recognize that non-pharmacological interventions in many instances are the first choice treatment of behavioral disturbances. However, this is beyond the scope of this current review.

Literature Search {#Sec3}
-----------------

Assisted by the University Library in Bergen, PICO-based \[problem/population (P), intervention (I), comparison (C) and outcomes (O) (Table [1](#Tab1){ref-type="table"})\] literature searches were conducted in October 2015, covering medical peer-reviewed publications (original papers and systematic reviews) published between 1990 and October 2015. We searched MEDLINE, EMBASE, CINAHL, PsychINFO and Cochrane libraries (Fig. [2](#Fig2){ref-type="fig"}). Key words included MESH terms and phrases synonymous with "pain," "treatment," and "dementia" (the online appendix---see the electronic supplementary material---provides a complete overview of the different MESH terms). The literature searches were then collated and all the authors discussed inclusion of publications (see Table [1](#Tab1){ref-type="table"} for a description of inclusion and exclusion criteria). To guarantee that we recognized all the relevant publications, two different researchers (B. S. H., E. F.) independently selected the relevant studies. Only articles in the English language were included. On the basis of the exclusion criteria listed in Table [1](#Tab1){ref-type="table"}, the authors screened potential manuscripts at the abstract level and applied the review protocol of described inclusion and exclusion criteria on selected full texts; we also searched through the reference lists of the full-text publications. The authors discussed in group meetings all manuscripts read in full text and borderline exclusion cases.Table 1Defined PICO-based search strategy, and listed exclusion criteriaPopulationPatients with Alzheimer's disease or undefined dementiaInterventionPain treatment defined as a pharmacological intervention in which the medications employed are named and dosages listedComparisonAll studies using standard care as usual group comparison or other valid comparison alternatives before/after comparisonOutcomeOnly studies employing quantitative measures and analyses were included. Outcomes included assessment of pain (yes/no or pain intensity) as well as assessment of pain-related behavior, e.g., neuropsychiatric symptomsExclusion criteria(1) Qualitative studies, (2) single case studies and those including less than ten patients, (3) methodology papers, (4) study protocols, (5) animal studies, (6) non-pharmacological studies, (7) deep brain stimulation and other experimental studies, and (8) conference abstracts. On the basis of these exclusion criteria, the authors screened potential manuscripts at the abstract level and applied the review protocol of described inclusion and exclusion criteria on selected full texts; we also searched through the reference lists of the full-text publications*PICO* problem/population, intervention, comparison and outcomesFig. 2PRISMA based flow chart over the literature search, selection and review process

In order to extract and synthesize the content of the manuscripts included in this review, the authors agreed on the content to be extracted and developed a data-extraction table with cells for content to be extracted from the manuscripts. The table was piloted and discussed in the group. A minimum of two of the co-authors read through each publication independently and then verified the data extraction in a discussion. Any unclear material was raised in group discussions. When applicable, the following was extracted from each publication: full manuscript reference, number of participants, study design and method, type of intervention (specifically, type of pain medication) and control condition, time to follow-up, and study setting and outcomes. Finally, the authors agreed upon the organizing themes of Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}, and the grading of evidence according to an adapted Oxford Centre for Evidence-based Medicine---Levels of Evidence document. This system allows author to grade both studies and reviews on the basis of quality factor such as sample homogeneity, follow-up, definition of comparison group, and use of validated and relevant tests. The ten different levels of evidence defined in the system are then translated into grades of recommendation (A--D).Table 2Clinical studies investigating the efficacy of analgesic treatment on pain intensity or typical behavior of pain in people with advance dementiaPain medicationAuthors, year, nationality, grade^a^PopulationMethodOutcomesFindingsParacetamol/acetaminophenChibnall et al. \[[@CR35]\], 2005, USA, B25 NH patients with moderate-to-severe dementia (degenerative 13, AD 4, multi-infarct dementia 4)Randomized, double-blind, placebo-controlled, crossover trial; 4 weeks placebo, 4 weeks treatmentDCM\
CMAI; no pain toolPatients were more active and spent more time in social surroundings and interacting with others (*p* \< 0.05, *η* ^2^ from 0.15 to 0.25); no effect on agitation, emotional well-being or as-needed psychotropic medicationBuffum et al. \[[@CR34]\], 2004, USA, B39 NH patients with dementia (AD/VaD) and pain rel. degenerative joint disease; mean MMSE 4.3 and GDS 5.7Double-blind, placebo-controlled, crossover 4-week trial investigating scheduled (650 mg × 4/day) vs. as-needed acetaminophen administrationDS-DATNo differences were found between scheduled or as-needed acetaminophen application; 2600 mg/day acetaminophen is inadequate for NH patients with degenerative joint disease1 % solution of lidocaine, a local anestheticBenedetti et al. \[[@CR40]\], 2006, I, B28 people with AD; mean 74 years; baseline MMSE 22--25, after 1 year 13--20Placebo-related analgesic study with open (expected)/hidden (unexpected) paradigm lidocaine gelNRS--self ratingPeople with dementia/reduced FAB show reduced placebo effect of analgesic treatment \[post hoc Tukey test, *q*(42) = 13.524, *p* \< 0.001\]. Analgesics should be increased to compensate for the loss of placebo effectMorphineManfredi et al. \[[@CR36]\], 2003, USA, B47 people with dementia (unknown type) from one NH (1999--2001); mean 86 years; MMSE \<20; CMAI ≥40All patients received placebo for 4 weeks followed by treatment with oxycodone 20 mg/day or morphine 20 mg/dayCMAI; no pain tool25 patients completed the study; no differences in agitation between placebo and opioid phases, though patients ≥85 years old (*N* = 13) were less agitated (CMAI score −6.4; 95 % confidence interval −10.96 to −1.8). No group differences in sedation; high drop-out rateKlapwijk et al. \[[@CR39]\], 2014, NL, C24 dying patients with most severe dementia (type unknown); two NHs; median age 91 yearsObservational study of the last days of life; small sample size; pain instruments not validated for EoL carePAINAD\
DS-DAT\
EOLD-CAD\
MMSEMean 4.3 observations per patient; all participants received morphine (dosage not available). Low symptom burden but direct effect of morphine was not estimatedVitamin DBjörkman et al. \[[@CR33]\], 2008, Finland, B202 NH patients with pain and dementia (type unknown); mean 85 ± 7 years; CPS 4.9 ± 1.4, range 1--6Randomized, double-blind placebo-controlled 6-month trial with vitamin D supplement in three groups: 0, 400 or 1200 IU cholecalciferolRAI\
PAINAD\
DS-DAT\
CPS38--84 % of the patients were in pain; vitamin D deficiency was not associated to pain or pain behavior; prevalence of painlessness or pain scores not changed after vitamin D treatment*AD* Alzheimer's disease, *CMAI* Cohen-Mansfield Agitation Inventory \[[@CR86]\], *CPS* Cognitive Performance Scale, *DCM* Dementia Care Mapping, *DS-DAT* Discomfort Scale--Dementia of Alzheimer Type \[[@CR87]\], *EoL* end-of-life, *EOLD-CAD* End-of-Life in Dementia--Comfort Assessment in Dying \[[@CR88]\], *FAB* Frontal Assessment Battery \[[@CR89]\], *GDS* Global Deterioration Scale \[[@CR90]\], *I* Italy, *MMSE* Mini-Mental State Examination \[[@CR95]\], *NH* nursing home, *NL* Netherlands, *NRS* Numerical Rating Scale, *PAINAD* Pain Assessment in Advanced Dementia \[[@CR91]\], *RAI* Resident Assessment Instrument, *rel* related to, *VaD* vascular dementia^a^Quality grade according to the Oxford grading of evidenceTable 3Clinical studies investigating the efficacy of analgesic combination therapy in people with advance dementiaPain medicationAuthors, year, references, nationality, grade^a^PopulationMethodOutcomesFindingsParacetamol/acetaminophen, NSAIDs, oral or parenteral opioidHendriks et al. 2014--2015, \[[@CR38], [@CR48]\], NL, C330 dying people with dementia from 34 NHs (2007--2011); 43 % had AD2 weeks after death retrospective questionnaire to investigate association between QoL and pain11-item QUALID; no pain toolIn the last week of life, 52 % were found to be in pain; no differences between patients between advanced and less advanced dementia; 77 % received opioids (90 mg/24 h; 88 % by injection); 43 % opioid monotherapy, 57 % opioids + paracetamol. Cannot determine the most effective treatment of symptomsParacetamol, morphine, buprenorphine, and/or pregabalinHusebo et al. 2011--2014, \[[@CR7], [@CR37], [@CR49], [@CR50]\], N, A352 NH patients with advanced dementia (type unknown) and agitation from 60 NH clustersCRCT over 12 weeks; NH clusters were randomized to an SPTPCMAI\
NPI-NH\
MMSE\
MOBID-2 Pain Scale\
ADLAgitation reduced in the SPTP group (average reduction 17 % (*p* \< 0.001, 95 % confidence interval −3.7 to −10.3) \[[@CR37]\]. Verbally agitated behaviors, physically non-aggressive behaviors, and aggressive behaviors improved after 8 weeks (*p* \< 0.001, *p* = 0.008, *p* = 0.037, respectively) \[[@CR50]\]. Mood syndrome improved (*p* \< 0.001), including depression (*p* = 0.025), apathy (*p* = 0.017), sleep (*p* = 0.050), and appetite (*p* = 0.005) \[[@CR49]\]. Pain reduced in SPTP group compared with control (*p* \< 0.001) at week 8, and pain scores worsened during washout (*p* = 0.022). Acetaminophen improved ADL function (*p* = 0.02) \[[@CR7]\]*AD* Alzheimer's disease, *ADL* Activities of Daily Living \[[@CR52]\], *CMAI* Cohen-Mansfield Agitation Inventory \[[@CR86]\], *CRCT* cluster randomized clinical trial, *MMSE* Mini-Mental State Examination \[[@CR95]\], *MOBID* Mobilization-Observation-Behavior-Intensity-Dementia \[[@CR42]\], *N* Norway, *NH* nursing home, *NL* Netherlands, *NPI-NH* Neuropsychiatric Inventory--Nursing Home version \[[@CR92]\], *NSAID* nonsteroidal anti-inflammatory drug, *QoL* quality of life, *QUALID* Quality of Life in Late-Stage Dementia \[[@CR93]\], *SPTP* stepwise protocol of treating pain^a^Quality grade according to the Oxford grading of evidenceTable 4Responsiveness of pain assessment instruments to assess change in pain intensity after initiated pain treatment in people with dementiaAuthor, year, referencePain toolSetting and participantsMethodFindingsMorello et al. 2007, \[[@CR43]\]EPCA-2340 NVC-OP, living in NHsRandomized study: 284 people were treated for pain (112 received opioids; 171 received non-opioids; 57 did not receive any analgesics); investigators not blindedES and SRM were correlated with changes in EPCA-2 scores and GCS, opioid and non-opioid dosages and demonstrated satisfactory responsiveness of the EPCA-2Cohen-Mansfield 2008, \[[@CR44]\]PAINE^a^ PADE^a^ PAINAD^b^\
CNPI^b^\
OPBAI^b^36 people with dementia (MMSE ≤20)Before and after pain treatment evaluation by self-report and proxy rating; pain treatment with acetaminophen (*N* = 29), combination acetaminophen + oxycodone (*N* = 6) was compared to patients without pain; investigators not blinded; small sample sizeIt is suggested that PAINE and PADE had strongest detection in treatment effectsRat et al. 2011, \[[@CR45]\]Algoplus^®c^109 inpatients; MMSE \<15, with acute pain lasting \<2 weeksMulticenter, cross-sectional study including five settings. Algoplus^®^ sensitivity to change was tested by movement-induced change during movement before and after starting with WHO level I--III analgesics or non-pharmacological treatment; investigators blinded109 acute pain patients received level I drug (37 %), II drug (30 %), III drug (23 %), others (3 %). Paired comparisons by Wilcoxon's signed-rank found Algoplus^®^ scores before (3.1 ± 1.3) and after treatment (1.6 ± 1.1) comparable with changes on VAS and NRSHusebo et al. 2014, \[[@CR42]\]MOBID-2 Pain Scale352 people with advanced dementiaMulticenter, cluster randomized trial including 18 NHs; SPTP with paracetamol, morphine, buprenorphine and/or pregabalin; assessments at baseline, week 2 and 4; investigators blindedSEM and SDC in connection with MOBID-2 Pain Scale measures indicate that the tool is responsive to a decrease in pain after SPTP. Satisfactory test--retest reliability demonstrated. Change scores ≥3 on total and subscales are clinically relevant and beyond measurement error*CNPI* Checklist of Nonverbal Pain Indicators \[[@CR94]\], *EPCA-2* Elderly Pain Caring Assessment 2 \[[@CR43]\], *ES* effect size, *GCS* global Clinical Score, *MMSE* Mini-Mental State Examination \[[@CR95]\], *MOBID* Mobilization-Observation-Behavior-Intensity-Dementia \[[@CR42]\], *NH* nursing home, *NRS* Numerical Rating Scale, *NVC-OP* non-verbally communicating older patients (age ≥65 years), *OPBAI* Observational Pain Behavior Assessment Instrument \[[@CR96]\], *PADE* Pain Assessment for the Dementing Elderly \[[@CR97]\], *PAINAD* Pain Assessment in Advanced Dementia \[[@CR91]\], *PAINE* Pain Assessment in Noncommunicative Elderly persons \[[@CR98]\], *SDC* smallest detectable change, *SEM* standard error of measurement, *SPTP* stepwise protocol of treating pain, *SRM* standard response mean, *VAS* Visual Analog Scale, *WHO* World Health Organization^a^Informant rating^b^Observation rating^c^Acute pain tool

We had a special focus on articles that described the responsiveness testing of observational pain assessment instruments. With responsiveness, we are not referring to standard error of mean, but to studies demonstrating that the instrument is responsive to pain treatment. However, general publications that focused on the development, validation, and testing of pain assessment tools were excluded, as these have previously been described in detail \[[@CR1], [@CR13], [@CR21], [@CR32]\].

Results {#Sec4}
=======

After exclusion of the doublets, the systematic search generated 3135 unique hits. Subsequently, B.S.H. and E.F. read the titles and abstracts and identified 124 papers for full-text evaluation, of which 79 manuscripts were potential primary studies and 49 were potential systematic reviews. A search through the reference lists of the included papers yielded no further publications. Eight studies yielding 12 publications met the selection criteria (Fig. [2](#Fig2){ref-type="fig"}). These were published between 2003 and 2014, with patient sample size ranging from 24 to 352, and number of nursing homes ranging from one to 18. Three studies were published by researchers from the USA, two from the Netherlands, and one study each from Finland, Italy, and Norway. The quality grading of evidence (grade A--D) is indicated in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Five of these studies included typical nursing home patients \[[@CR33]--[@CR37]\], two trials included dying people \[[@CR38], [@CR39]\], and one study had an experimental design with home-dwelling participants \[[@CR40]\]. In four studies \[[@CR33], [@CR36], [@CR37], [@CR39]\], the type of dementia was not specified among included participants, whereas one study included only people with AD \[[@CR40]\]; in another, almost half (43 %) of the patients had AD \[[@CR38]\]. The remaining two studies involved people with diagnoses of AD or VaD \[[@CR34]\] and multi-infarct, or degenerative dementia \[[@CR35]\]. Six studies investigated the efficacy of a monotherapy with paracetamol (acetaminophen), morphine, vitamin D, and lidocaine gel, while another two studies used several treatment options and a stepwise protocol of treating pain (SPTP) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).

We did not find intervention studies that included treatment with oral or topical nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, tricyclic antidepressants, tramadol, codeine, or buprenorphine as monotherapy.

Further, we found four papers that described the responsiveness testing of observational pain assessment tools (Table [4](#Tab4){ref-type="table"}).

Which Pain Assessment Tools for People with Dementia are Responsive to Change in Pain Intensity Scores? {#Sec5}
-------------------------------------------------------------------------------------------------------

Responsiveness is the "ability of an instrument to detect change over time in the construct to be measured" \[[@CR41]\]. Thus, a responsive observational pain tool is a prerequisite for proper treatment of pain in people with dementia to address the change in the total pain intensity score after pain treatment has been initiated \[[@CR21]\]. Psychometric property testing of such a tool should follow recent COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) recommendations \[[@CR41]\]. Four validation studies with comparator groups including between 91 and 352 patients have evaluated the responsiveness of several observational pain assessment tools \[[@CR42]--[@CR45]\] (Table [4](#Tab4){ref-type="table"}).

Morello et al. explored the psychometric properties of the Elderly Pain Caring Assessment 2 (EPCA-2), which rates the pain intensity in non-communicating elderly people by eight behavioral items with two dimensions: the signs outside and during care giving \[[@CR43]\]. Patients (*N* = 340) from three French hospitals were assessed by experienced observers (pairs of doctors and nurses) for 7 days, in order to study the patients' behavior in the absence of pain and during a presumed state of pain (before and after taking analgesics). The responsiveness of the EPCA-2 was demonstrated by changes of pain intensity scores that correlated highly to other change scores of the Global Clinical Score (GCS) and analgesic drug use (opioid subgroup *N* = 112, non-opioid subgroup *N* = 171), compared with the non-analgesic subgroup (*N* = 57).

Cohen-Mansfield conducted an open pain treatment trial to investigate the responsiveness of nine observational pain tools after pain treatment in 121 patients with dementia living in four nursing homes in Maryland \[[@CR44]\]. Patients (*N* = 36) with pain at baseline were treated following an analgesic protocol of paracetamol, oxycodone, or oxycontin. The study had three comparator groups: patients who were in pain at baseline and treated with the analgesic protocol; those with pain at baseline, but the primary caregiver did not follow the protocol; and those without pain (*N* = 58). Patients who followed the analgesic treatment protocol had a significant reduction of pain compared with the other two groups. The Pain Assessment in Noncommunicative Elderly persons (PAINE) and Pain Assessment for the Dementing Elderly (PADE) pain tools were highlighted as the most responsive to assess the change in pain intensity scores.

The third study, by Rat et al. conducted an open pain treatment trial to investigate the responsiveness of the acute pain instrument Algoplus^®^ in 91 French hospital patients with dementia \[[@CR45]\]. Acute pain was defined by a list of pain-inducing situations, such as traumatic injuries, fractures, abdominal pain, or bedsores. Algoplus^®^ sensitivity to change was tested during movement and after starting acute pain management with World Health Organization (WHO) level I drug, i.e., non-opioids (37 %), II drug, i.e., mild opioids (30 %), III drug, i.e., strong opioids (23 %), and others (3 %). Paired comparisons by Wilcoxon's signed-rank found Algoplus^®^ scores of 3.1 ± 1.3 before and 1.6 ± 1.1 after treatment, comparable to changes on the Visual Analog Scale (VAS) and Numerical Rating Scale (NRS).

Our own group investigated the responsiveness of the Mobilization-Observation-Behavior-Intensity-Dementia (MOBID)-2 Pain Scale, using data from a cluster randomized clinical trial that included 352 Norwegian nursing home patients with advanced dementia and agitation \[[@CR42]\]. Nursing home clusters were randomized to an SPTP with paracetamol, morphine, or buprenorphine, and/or pregabalin when neuropathic pain was suggested. This was a 12-week trial including a 4-week washout period after the SPTP. We followed the latest COSMIN recommendations to assess the responsiveness of the MOBID-2 Pain Scale. Test--retest reliability between baseline and week 2 (*N* = 163), and weeks 2 and 4 (*N* = 159) was examined in patients not expected to change (control), using the intraclass correlation coefficient (ICC~2.1~), standard error of measurement (SEM), and smallest detectable change (SDC). Responsiveness was assessed by testing six a priori-formulated hypotheses about the relationship between change scores on the MOBID-2 Pain Scale and other outcomes. SEM and SDC indicated that the MOBID-2 Pain Scale is responsive to a decrease in pain after analgesic treatment. Satisfactory test--retest reliability was demonstrated. Change scores of ≥3 on total and subscales were clinically relevant and beyond measurement error.

Which Analgesics are Efficacy-Tested by Clinical or Randomized Controlled Trials Including People with Dementia? {#Sec6}
----------------------------------------------------------------------------------------------------------------

### Paracetamol {#Sec7}

The use of paracetamol is recommended as the first-line therapy in people with dementia \[[@CR14]\] and is to date the most used analgesic in nursing home patients worldwide \[[@CR46], [@CR47]\]. We found two studies conducted between 1998 and 2015 that investigated the efficacy of paracetamol (administered as monotherapy) on pain and/or behavioral disturbances in people with dementia (Table [2](#Tab2){ref-type="table"}).

Chibnall et al. conducted a placebo-controlled, crossover trial for 4 weeks including 25 people with moderate to severe dementia \[[@CR35]\]. Twenty-five patients received 4 weeks' paracetamol 1 g each 8 h and 4 weeks' placebo in random order, with a 1-week washout period; 23 patients completed both study phases. The effect was assessed with Dementia Care Mapping (DCM) and Cohen-Mansfield Agitation Inventory (CMAI) \[[@CR35]\]. Results demonstrated that patients in the intervention phase were more active and interacted with each other, and spent more time in social surroundings. Paracetamol, however, did not ameliorate agitation, improve emotional well-being, or reduce the use of as-needed psychotropic medication. A validated pain assessment tool was not used.

Buffum et al. included 39 nursing home patients with advanced dementia and degenerative joint diseases in a placebo-controlled, crossover trial for 4 weeks (each arm lasted for 2 weeks) to investigate the impact of regularly scheduled analgesic treatment compared with as-needed administration \[[@CR34]\]. Patients randomized to the intervention group received 2.6 g paracetamol in 24 h. The treatment effect was assessed by the Discomfort Scale--Dementia of Alzheimer Type (DS-DAT). No differences in pain and/or discomfort were found between the groups. It was suggested, however, that the paracetamol dosage was rather too low to ameliorate existing pain.

### Opioids {#Sec8}

We found two studies that investigated the efficacy of morphine and oxycodone (as a monotherapy) on neuropsychiatric symptoms, pain, and overall symptom management in people with dementia (Table [2](#Tab2){ref-type="table"}). Manfredi et al. conducted a small double-blinded, crossover study with fixed treatment order for 8 weeks and included 47 people with moderate to severe dementia and behavioral disturbances from one nursing home \[[@CR36]\]. Participants started with 4-week placebo treatment, and after a 1-day interval, a long-acting opioid (long-acting oxycodone 10 mg every 12 h, or for patients who could not swallow pills, long-acting morphine 20 mg once a day, via a feeding tube) for the next 4 weeks. This approach did not include a randomized order of administration. The efficacy of opioid treatment on agitation was assessed by the CMAI, and no significant differences were found between the placebo and active phases in 25 participants who completed the study. Sub-analyses demonstrated, however, that 13 patients older than 84 years were less agitated. An observational pain assessment instrument was not used.

The second study, by Klapwijk et al. was an open prospective, observational follow-up trial in two Dutch nursing homes, and included 24 people with severe dementia who were expected to die within the next 7 days \[[@CR39]\]. The judgment that the patient was perceived as dying was based on an estimation made by the treating physician and responsible nurse. Symptoms of discomfort, pain, and suffering were recorded twice a day using the Pain Assessment in Advanced Dementia (PAINAD), DS-DAT, and End-Of-Life in Dementia--Comfort assessment in Dying (EOLD-CAD) scales, and an adapted version of the Mini-Suffering State Examination (MSSE). Pain and distressing symptoms were treated with morphine. Each patient was observed several times (mean 4.3) until they died, demonstrating low intensity scores of pain and other symptoms such as dyspnea and fear. However, the direct effect of morphine on pain or other distressing symptoms, and the exact dosages, were not available.

### Lidocaine (1 % Solution) {#Sec9}

Benedetti et al. included 28 non-consecutive, communicative, home-dwelling patients with AD and 16 healthy volunteers matched for sex and age (mean 74 years) \[[@CR40]\]. Participants were invited to take blood samples in the laboratory. This procedure is often described as a burning sensation and, thereby, patients are treated with the local anesthetic lidocaine (1 % solution). In the open (expected) condition, the drug was applied in full view of the patient, whereas in the hidden (unexpected) condition, the same dose of drug was administered with the patient completely unaware that a local anesthetic was being applied. To justify the lack of lidocaine application, the patients were told that lidocaine would be applied or not. Patients rated their pain sensation on an NRS. Results demonstrated that AD patients showed reduced placebo component of the analgesic treatment. Loss of the placebo-related mechanism reduced treatment efficacy, such that a dose increase was necessary to produce adequate analgesia.

### Vitamin D {#Sec10}

Björkman et al. investigated the efficacy of vitamin D (cholecalciferol) treatment on pain during a 6-month, double-blind, placebo-controlled clinical trial \[[@CR33]\]. The study participants were assessed by the Resident Assessment Instrument (RAI) and DS-DAT (Table [2](#Tab2){ref-type="table"}). Two hundred and two nursing home patients with cognitive impairment were randomized to three groups, which were treated with 0, 400, or 1200 IU cholecalciferol. Despite growing evidence of the potential benefit of vitamin D supplementation on pain intensity, the etiology was still vague after 6 months of treatment.

### Multi-Analgesic Drug Use {#Sec11}

We identified two studies that investigated multi-analgesic stepwise drug use to treat pain and/or neuropsychiatric symptoms in people with dementia (Table [3](#Tab3){ref-type="table"}). Results were published in six different articles \[[@CR7], [@CR37], [@CR38], [@CR48]--[@CR50]\]. The first study, by Hendriks et al. included 330 dying people with dementia from 34 Dutch nursing homes (2007--2011) \[[@CR38]\]. The End of Life in Dementia (EOLD) study is an open, longitudinal, observational trial with a 3.5-year follow-up, until death. The responsible physicians performed assessments at baseline, semiannually, and 2 weeks after death. The occurrence of pain, dyspnea, and agitation were scored dichotomously (present/not present). The quality of life was assessed by the Quality of Life in Late-stage Dementia (QUALID) scale. Independent of the stage of dementia, 52 % of the patients were registered as in pain in the last week of life. Most of the patients (77 %) received opioids (90 mg/24 h; 88 % by injection); opioid monotherapy was applied to 43, and 57 % of the dying received morphine combined with paracetamol. The second publication by Hendriks and colleagues investigated the associations between the symptoms of pain and agitation, as well as between the stage of dementia and symptoms \[[@CR48]\]. They found that the prevalence of pain ranged from 47 % to 68 % across the semiannual assessments, and increased to 78 % in the last week of life. Symptom treatment changed in particular at the end of life. Pain was treated mostly with paracetamol (34--52 %), and at the end of life with parenteral opioids (44 %). Pain and agitation were common and frequently persisted in residents with dementia during nursing home stay, but symptom management intensified only at the end of life. The authors concluded that symptom control may be suboptimal starting at admission, and this requires a stronger focus on symptom control at earlier stages than only the last days or weeks of life.

Our own study, described earlier, was a cluster randomized clinical trial over 12 weeks, including 352 people with advanced dementia and neuropsychiatric symptoms from 18 nursing homes in Norway \[[@CR37]\]. Patients randomized to intervention received an SPTP with paracetamol, morphine, buprenorphine, and/or pregabalin on the basis of ongoing treatment and individual needs. The MOBID-2 Pain Scale, CMAI, Neuropsychiatric Inventory--Nursing Home version (NPI-NH), and the Activities of Daily Living (ADL) scales were regularly used for data collection at baseline, weeks 2, 4, 8, and 12 (weeks 8--12 washout). Analyses found agitation reduced in the SPTP group after 4 weeks (average reduction 17 %; *p* *\<* 0.001). Verbally agitated behaviors, physically non-aggressive behaviors, and aggressive behaviors improved significantly (*p* *\<* 0.001, *p* = 0.008, *p* = 0.037, respectively) after 8 weeks \[[@CR50]\]. Mood syndrome improved (*p* *\<* 0.001), including depression (*p* = 0.025), apathy (*p* = 0.017), sleep (*p* = 0.050), and appetite (*p* = 0.005), but not irritability (*p* = 0.092) and anxiety (*p* = 0.125) \[[@CR49]\]. Pain was reduced in the SPTP group compared with control (*p* *\<* 0.001) at week 8, and MOBID-2 scores and agitation worsened during the washout period (*p* = 0.022). Examining different analgesic treatments, patients receiving paracetamol improved significantly in their ADL function (*p* = 0.022) \[[@CR7]\].

Which Primary and Secondary Outcome Measures Were Used? {#Sec12}
-------------------------------------------------------

Five studies used a pain assessment instrument (NRS--self-rating, DS-DAT, MOBID-2 Pain Scale, RAI, and PAINAD) to investigate the efficacy of treating pain on pain intensity. Of these instruments, the MOBID-2 Pain Scale is the only instrument that has been tested for responsiveness in dementia patients \[[@CR42]\] (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). Some papers investigated the efficacy of treating pain on indirect measures, such as agitation, neuropsychiatric symptoms, quality of life, activity, and more general symptom control at the end of life (CMAI, NPI-NH, ADL, QUALID, DCM, EOLD-CAD). For the QUALID, a measure for quality of life in dementia, there has been only one study on responsiveness, which showed that it was not responsive to changed neuropsychiatric symptoms \[[@CR51]\]. Quality of life was related to neuropsychiatric symptoms at baseline and after intervention, but not related to change scores. The instruments that measure neuropsychiatric symptoms (CMAI and NPI-NH) have been proven responsive to several (non-)pharmacological behavioral interventions. CMAI was also responsive to pain medication in one study \[[@CR37]\]. In the same study sample, the NPI-NH subscale mood was also responsive to pain medication \[[@CR7]\], as was the ADL measure \[[@CR52]\]. We could not find other studies in which responsiveness was tested on the effect of pain medication in a dementia population.

The EOLD-CAD is an instrument that measures quality of dying and performs well in terms of validity, reliability, and feasibility \[[@CR53]\]. However, there are no data on its responsiveness, or studies showing relevant differences after pain interventions. The DCM tool (a direct observation tool, developed for use in nursing homes) has been shown to be able to pick up changes in activity after an intervention with paracetamol, although no formal responsiveness test results are presented \[[@CR35]\].

Discussion {#Sec13}
==========

This article adds to previous literature reviews of the assessment and treatment of pain in people with dementia \[[@CR1], [@CR12], [@CR21], [@CR54], [@CR55]\], with a particular focus on studies investigating the direct efficacy of analgesics on pain intensity. In this context, it was also important to give an overview of responsive tools that are able to assess change in the total pain intensity score after initiation of the treatment. We further extended our search to studies that included dying people with dementia because it is widely acknowledged that dementia is a life-limiting disease with considerable pain and symptom burden in the last days and hours of life \[[@CR31], [@CR56], [@CR57]\].

Methodological Perspectives {#Sec14}
---------------------------

We found few studies employed a blinded, controlled trial design; they generally included few participants; and unfortunately, most of the publications did not sufficiently describe management of dropouts. The possible lack of statistical power and selection bias means that the studies in this review may have methodological and statistical biases. There was also a wide variation both in the interventions used and in the study designs.

Hence, a limitation with our systematic literature review is the limited possibility to compare the studies in terms of quality and methods. Conclusive recommendations based on aggregated evidence are at this point difficult to provide. In addition, with our strict inclusion criteria, we cannot exclude the possibility of publication bias.

Responsiveness of Pain Assessment Tools {#Sec15}
---------------------------------------

Thus far, few studies have investigated the responsiveness of pain assessment tools used in people with dementia or non-communicating elderly people. Responsiveness is of critical importance for clinicians and researchers to be confident that an improvement in individual patients after treatment is not merely measurement error. The results of the few responsiveness studies of the single measurement tools are challenging to interpret because treatment groups were partly small with different treatment and measurement approaches.

The initial step to improve pain treatment is proper assessment by monitoring the change of pain intensity to the pain treatment intervention. We found four studies that reported the responsiveness of the observational tools EPCA-2 \[[@CR43]\], MOBID-2 Pain Scale \[[@CR42]\], PAINE and PADE \[[@CR44]\], developed and tested for nursing home patients with dementia, and the Algoplus^®^ for the evaluation of acute pain treatment in hospital \[[@CR45]\]. However, the evidence to support the use of these pain tools is rather limited. Recent requirements by the COSMIN group recommended a checklist for assessing the methodological quality of health status measurement instruments to improve the psychometric property testing \[[@CR41]\]. Until now, only the MOBID-2 Pain Scale followed the latest COSMIN recommendations and examined measurement error by the SEM and the SDC, which are important parameters for judging change scores in large clinical trials investigating the efficacy of analgesics on pain intensity \[[@CR7]\]. To the best of our knowledge, there are currently no other instruments that have been responsiveness tested for use in dying people with dementia \[[@CR53]\]. Consequently, the direct efficacy of pain and symptom management cannot currently be monitored by a responsive tool at the end of life in these individuals. Studies on responsive non-verbal pain assessment tools in the end-of-life setting are needed.

Pain Assessment in Dementia {#Sec16}
---------------------------

Today, there is extensive ongoing work to develop and test appropriate pain assessment instruments for people with advanced dementia \[[@CR58]\]. Most of the instruments are based on the assumption and recommendations of the American Geriatrics Society (AGS) Panel that pain can be expressed by changes in facial expression (e.g., frowning), vocalization and verbalization (e.g., groaning, mumbling), and body movements \[[@CR59], [@CR60]\]. The AGS Panel suggests the following additional behavioral changes that may be triggered by untreated pain: changes in interpersonal interactions (e.g., aggressive, combative, resisting care), changes in activity patterns or routines (e.g., wandering, appetite, sleep), and mental status changes (e.g., crying, confusion, irritability). One important clinical and research dilemma is the difficulty of differentiation between typical behavior related to pain and behavior that is caused by the dementia process itself. These behaviors may present in a similar way for the observer \[[@CR21]\]. Importantly, most scales are validated for ascertaining the presence of pain, but not the pain intensity. In most scales, we do not know if scoring a higher number of behavioral items also means more pain. In addition, in these scales, all behavioral items that can be scored are given the same weight. No studies have tried to differentiate pain intensity between these items, and therefore, we cannot say if, for instance, guarding, frowning, or screaming is an indication of more pain. Consequently, we need more research on the responsiveness of these behavioral pain observation scales, and these should not only be studied on the change of sum scores. Sensitive responsive instruments are needed for the evaluation of pain treatment, and they will also require weighing of the different behavioral signs.

The psychometric property developments (validity, reliability, and responsiveness) of available instruments are ongoing tasks. General agreement exists that the assessment of pain in people with dementia should be based on the observation of the patient's pain behavior during activities of daily living and/or gentle guided standardized movements, because pain avoidance may mask pain behavior \[[@CR21], [@CR58], [@CR60]--[@CR62]\]. The interpretation of pain behavior into pain intensity scores is a necessary task because the presence of the behavior does not automatically mean clinically significant pain intensity. As demonstrated by the MOBID-2 Pain Scale, the differentiation between pain related to the muscle-skeletal system and internal organs, head, and skin is relevant for the clinician, since different locations of pain may require different treatment approaches. The nursing staff need to have their daily observations systematized and corroborated by a validated total pain intensity score. A cut-point will indicate when to contact the physician who continues further evaluations and treatment.

Pharmacological Management of Pain in Dementia {#Sec17}
----------------------------------------------

We identified eight randomized prospective treatment trials with a comparator group or open studies with more than ten participants that investigated the direct effect of analgesics on pain and/or neuropsychiatric symptoms including people with dementia. Importantly, only four of these studies used a pain assessment instrument to monitor the analgesic treatment effect on pain intensity. There is limited evidence as to the effect of using paracetamol and morphine. We are not aware of studies that included treatment with NSAIDs, tramadol, or codeine. However, Stein et al. conducted a 3-month, randomized, controlled trial to investigate the efficacy of an educational program for nursing home staff to improve pain treatment and indirectly reduce the use of NSAIDs \[[@CR63]\]. The education of staff resulted in a reduction of the time of NSAID use from 7 to 2 days and from 7 to 6 days in the control group. Interestingly, the reduction did not worsen the pain \[[@CR63]\]. Buprenorphine and pregabalin have only been used in one large, cluster randomized, controlled trial that offered a stepwise approach to treating pain \[[@CR37]\].

Although paracetamol is traditionally the most used analgesic drug in nursing homes \[[@CR46]\], we found only two trials that investigated the efficacy of this treatment on pain intensity and/or behavioral disturbances in people with dementia. Both studies were randomized, placebo-controlled, crossover trials and demonstrated inconsistent results. Chibnall included 25 patients who received 4 weeks of paracetamol (3 g/day) and 4 weeks of placebo \[[@CR35]\]. Patients randomized to the intervention group were more active and spent more time in social surroundings. The efficacy on pain intensity scores was not investigated by a validated pain tool. Buffum et al. investigated the efficacy of regularly scheduled paracetamol for discomfort in people with advanced dementia over 4 weeks (2-week treatment with scheduled vs. 2-week treatment with as-needed administration) \[[@CR34]\]. Assessed by the DS-DAT, regular use of paracetamol did not confer any benefit compared with as-needed administration of the drug. Interestingly, the authors found that a dosage of 2600 mg paracetamol per day was not adequate to ameliorate pain in connection with degenerative joint disease. Agitation, as well, was not reduced by the treatment \[[@CR34]\]. The only trial that directly investigated the effect of morphine monotherapy on pain intensity was a placebo-controlled, crossover trial including 47 nursing home patients with dementia \[[@CR36]\]. Manfredi et al. found reduction of agitation in patients aged 85 or older, suggesting that opioids used in very old patients may be a beneficial treatment for agitation \[[@CR36]\]. The impact on pain intensity scores was not assessed. All the three studies were small and underpowered crossover trials; the results are challenging to interpret because of this and because of the lack of pain assessment instruments or low doses of paracetamol.

Two other placebo-controlled trials need attention because of their robust methodologies, sample sizes, and innovative research questions. Benedetti et al. included 28 people with mild to moderate AD; they were younger (mean 74 years) and lived at home \[[@CR40]\]. Using lidocaine gel during a painful procedure, the investigators demonstrated a reduction of the placebo component in patients with dementia. It was concluded that pain treatment should be adjusted to compensate for the loss of placebo effect \[[@CR40]\]. The other study, by Björkman et al. included 202 people with dementia and explored the efficacy of treating pain with vitamin D supplementation in three groups \[[@CR33]\]. Pain was assessed by three different pain tools (RAI, PAINAD, and DS-DAT). However, the authors did not find any effect of vitamin D on pain or pain behavior; neither prevalence of painlessness nor pain scores changed after vitamin D treatment \[[@CR33]\]. One large cluster randomized study supported guidelines from the AGS panel by a stepwise protocol of treating pain in people with dementia demonstrating clinically relevant agitation and pain \[[@CR37]\]. The study demonstrated that low doses of morphine and buprenorphine were well tolerated and ameliorated pain in people with dementia. Also paracetamol was a safer alternative medication than psychotropic drugs and improved activities of daily living \[[@CR7]\]. In people with neuropathic pain, pregabalin significantly reduced the pain intensity scores \[[@CR7]\]. Finally, the mood syndrome was improved by individual pain treatment \[[@CR49]\]. However, this study was not placebo controlled and the results should be validated by a well powered trial using active and placebo analgesics.

Pain Treatment in Dying Patients with Dementia {#Sec18}
----------------------------------------------

The needs of people with dementia at the end of life may be different from those with different diseases \[[@CR64], [@CR65]\]. Thus, it was important for us to also include two observational studies of palliative treatment that described the effectiveness of analgesics on pain intensity scores or symptom burden in these individuals. The prospective observational study by Klapwijk et al. observed 24 patients from the day when the person was perceived as dying and to the day of death \[[@CR39]\]. All patients received morphine subcutaneously. Although the most used pain assessment instruments (PAINAD, DS-DAT) were not validated for this end-of-life situation, the multidisciplinary team was pleased with the pain and symptom relieving effect of the treatment \[[@CR39]\]. The study by Hendriks et al. included 330 dying patients, who were retrospectively (up to 2 weeks after death) assessed by 103 elderly care physicians \[[@CR38], [@CR48]\]. Fifty-two percent of the patients were affected by pain, which was dichotomized as present or not, and were treated with 90 mg morphine/24 h on the day of death. Both studies are groundbreaking contributions to the assessment and treatment of pain and burdensome symptoms in dying people with dementia, although the study by Klapwijk et al. was somewhat underpowered and the study by Hendriks et al. retrospective. Both studies were observational; thus, the direct effect of the analgesics was difficult to interpret.

Pain research in dying people with dementia is of particular interest for several reasons. First, research including elderly patients often excludes people with dementia and, until now, especially dying people with dementia \[[@CR66]--[@CR68]\]. Further, palliative care for cancer patients cannot necessarily be transferred to dying people with dementia \[[@CR69]\]. These individuals are neither able to describe the pain nor the pain treatment effect or side effects. Third, the nature of dementia leads to reduction of the neurotransmitter acetylcholine, responsible for neuromuscular junction and muscle activities, and the autonomic, sympathetic, and parasympathetic nervous system. Consequently, drugs that affect the cholinergic systems (anticholinergic drugs) can have very dangerous effects, ranging from paralysis to convulsions \[[@CR70]\]. Importantly, most of the drugs used in palliative care (morphine, scopolamine, or midazolam) to relieve pain and distressing symptoms have anticholinergic side effects. A self-fulfilling prophecy may be the case when a patient with dementia is wrongly identified as dying and then receives this treatment, hastening the death. These challenges argue for the urgent need for clinical studies, disease-specific guidelines, and implementation of research-based knowledge \[[@CR31]\].

Analgesic Drug Prescription {#Sec19}
---------------------------

Fifteen years ago, researchers echoed that people with advanced dementia have a substantial risk for undetected or undertreated pain. Morrison and Siu examined the treatment of pain following hip fractures in a prospective cohort study and found that people with advanced dementia received only one-third the amount of morphine compared with cognitively intact patients \[[@CR71]\]. Another study, by Closs et al. explored analgesic prescription according to cognitive status in nursing home patients and found no differences in pain scores, but administration of opioid and non-opioid analgesics were highest for residents without dementia \[[@CR72]\]. Results are supported by a more recent study from the USA, which identified nursing home patients with similar pain-related diagnoses; patients without dementia received significantly more opioids compared with those with cognitive impairment, despite higher pain intensity scores based on interviews and use of a numeric rating scale \[[@CR73]\]. In addition, there are many other studies that confirm the under-treatment of pain in people with dementia in the community, residential care settings, nursing homes, and hospitals \[[@CR3]\].

Nevertheless, times are changing. Recent prevalence studies demonstrated new trends of analgesic drug use. In the Kungsholmen Study, 46 % of 2610 people with dementia used at least one analgesic drug compared with 25 % of those without dementia \[[@CR5]\]. Another nationwide Swedish study demonstrated that centenarians (\>100 years) used more analgesics, anxiolytics, and hypnotics compared with younger patients \[[@CR74]\]. Indeed, the use of analgesics in 546 older people (\>85 years), with and without dementia, at home and in the nursing home, was high in Sweden and Finland. People with dementia used more paracetamol and likewise amounts of opioids compared with those without cognitive impairment \[[@CR75]\]. In addition, the use of strong opioids (e.g., transdermal fentanyl) was higher in people with dementia in Finland \[[@CR76]\]. In Danish nursing home patients, 41 % of all elderly receive opioids, and those with dementia and nursing home residents have a higher chance of receiving opioids \[[@CR77]\].

Most importantly, none of these studies reported better accuracy of pain assessment procedures, higher or improved pain management effects, or side effects of the treatment. This is of key importance because, based on Rhode Island Medicaid pharmacy claims about nursing home data, the US Food and Drug Administration (FDA) warned against morbidity and death related to the launch of long-acting opioids and the fentanyl transdermal system in opioid-naive people with AD \[[@CR78]\]. The authors found these drugs more frequently prescribed in those with advanced age and increased cognitive impairment. Recently, our own research demonstrated almost a doubling of analgesics, from 35 to 58 %, in Norwegian nursing homes during the last 10 years (2000--2011) \[[@CR47]\]. Results support recent trend analyses, which found that the use of analgesic drugs has been increasing rapidly over the last 8 years \[[@CR79]\]. It seems a paradox, however, that the crucial question remains: does the right patient receive the right medication for the proper indication at the right time \[[@CR1]\]? Although few of the recent studies suggest that analgesics are systematically under-prescribed, there is no information whatsoever on assessment, indication, evaluation, benefits, and harms \[[@CR80]\]. Thus, attaining a competent balance between under- and overuse of analgesics in people with dementia remains the most important challenge in this field.

Getting older is associated with a progressive decline of organ function, including typical changes such as reduced body mass index and lower body water percentage compared with a higher fat mass percentage \[[@CR70]\]. This is often combined with latent insufficiency of liver, a lower glomerular filtration rate of the kidneys, and cognitive function and biological alterations (such as a lower total brain mass) that impact the pharmacodynamics and pharmacokinetics of the drug. The absorption, distribution, and elimination of the drugs are altered, especially when several drugs are combined as a result of polypharmacy. Beers Criteria highlight a greater sensitivity to adverse events and higher risks of side effects in these people \[[@CR81]\]. However, we did not find studies that investigated pharmacodynamics and pharmacokinetics of analgesic drugs in people with dementia. Being aware of the potential lack of placebo effect in dementia and the potential effects of dementia on the brain--blood barrier certainly warrants those studies.

Pain Treatment Recommendations {#Sec20}
------------------------------

Although best practice recommendations for the assessment and treatment of pain in elderly people are available \[[@CR12], [@CR14], [@CR23], [@CR59], [@CR60], [@CR82]--[@CR84]\], clinicians in the nursing home setting may not routinely follow---or even be aware of---these guidelines. These expert groups predominantly endorse some specific drugs: paracetamol, strong opioids, and anticonvulsants \[[@CR12], [@CR14], [@CR23], [@CR59], [@CR60], [@CR82]--[@CR84]\]. Results of this review, however, underline the weak evidence base for all analgesics in dementia. Although the process of developing new evidence, the foundation of clinical guidelines and implementation, is not always linear, there is still a lack of well powered randomized controlled trials, and this prevents definite clinical guidelines being implemented among clinical staff \[[@CR85]\]. There is some evidence that paracetamol can be recommended, as it is relatively safe and some studies underline its efficacy. We therefore stress the need for placebo-controlled, randomized studies not only investigating the efficacy of NSAIDs, anticonvulsants, and morphine, but also withdrawal studies including patients who no longer are in need of these drugs.

Conclusion {#Sec21}
==========

To conclude, this review underlines the serious situation that pain management in especially advanced dementia is in at this moment: thorough pain assessment is poorly implemented and observational pain instruments have been scarcely tested for responsiveness; therefore, effective evaluation of pain management strategies is lacking and evidence for efficacy and safety of analgesics is largely missing. We emphasize the critical need for future research with well powered pain medication trials in persons with moderate to severe dementia using pain assessment tools that have been tested for responsiveness. Furthermore, there is a high need for studies investigating the end-of-life care in this population.
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